 |
|
recombinant vaccinia-multiepitope melanoma peptides-B7.1-B7.2 vaccine
A cancer vaccine consisting of an inactivated recombinant vaccinia virus encoding epitope peptides derived from melanoma-related HLA-A2-restricted tumor-associated antigens (TAAs), including Melan-A(27-35), gp100(280-288) and tyrosinase(1-9), and two co-stimulatory B7 proteins, B7.1 (CD80) and B7.2 (CD86). Upon administration, recombinant vaccinia-multiepitope melanoma peptides-B7.1-B7.2 vaccine may stimulate a cytotoxic T-lymphocyte response against melanoma cells that express TAAs which share epitopes with the epitope peptides expressed by the vaccine viral vector, resulting in tumor cell lysis; vaccine viral vector-expressed co-stimulatory proteins B7.1 and B7.2 may enhance the cytotoxic T-lymphocyte immune response to the TAAs. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Previous: | recombinant tyrosinase-related protein-2, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine, recombinant vaccinia-MUC-1 vaccine | | Next: | recombinant vaccinia-NY-ESO-1 vaccine, recombinant vaccinia-TRICOM vaccine, Rectoid, reduced glutathione-L-cysteine-anthocyanins gel, Refludan |
|
|
